CN1325403A - 胆汁酸取代的苯基链烯酰基胍、其制备方法、其作为药物或诊断剂的应用以及含有它们的药物 - Google Patents

胆汁酸取代的苯基链烯酰基胍、其制备方法、其作为药物或诊断剂的应用以及含有它们的药物 Download PDF

Info

Publication number
CN1325403A
CN1325403A CN99812751A CN99812751A CN1325403A CN 1325403 A CN1325403 A CN 1325403A CN 99812751 A CN99812751 A CN 99812751A CN 99812751 A CN99812751 A CN 99812751A CN 1325403 A CN1325403 A CN 1325403A
Authority
CN
China
Prior art keywords
alkyl
hydrogen
independently
phenyl
another
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN99812751A
Other languages
English (en)
Chinese (zh)
Inventor
A·维切特
A·恩森
E·法尔克
H－W·简森
W·克拉莫
J-R·施瓦克
H·J·朗
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Aventis Deutschland GmbH
Original Assignee
Aventis Pharma Deutschland GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Deutschland GmbH filed Critical Aventis Pharma Deutschland GmbH
Publication of CN1325403A publication Critical patent/CN1325403A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0055—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of at least three carbon atoms which may or may not be branched, e.g. cholane or cholestane derivatives, optionally cyclised, e.g. 17-beta-phenyl or 17-beta-furyl derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0055—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of at least three carbon atoms which may or may not be branched, e.g. cholane or cholestane derivatives, optionally cyclised, e.g. 17-beta-phenyl or 17-beta-furyl derivatives
    • C07J41/0061—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of at least three carbon atoms which may or may not be branched, e.g. cholane or cholestane derivatives, optionally cyclised, e.g. 17-beta-phenyl or 17-beta-furyl derivatives one of the carbon atoms being part of an amide group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
    • C07J9/005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane containing a carboxylic function directly attached or attached by a chain containing only carbon atoms to the cyclopenta[a]hydrophenanthrene skeleton

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN99812751A 1998-10-28 1999-10-15 胆汁酸取代的苯基链烯酰基胍、其制备方法、其作为药物或诊断剂的应用以及含有它们的药物 Pending CN1325403A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19849722.9 1998-10-28
DE19849722A DE19849722A1 (de) 1998-10-28 1998-10-28 Substituierte Phenyl-alkenoylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament

Publications (1)

Publication Number Publication Date
CN1325403A true CN1325403A (zh) 2001-12-05

Family

ID=7885948

Family Applications (1)

Application Number Title Priority Date Filing Date
CN99812751A Pending CN1325403A (zh) 1998-10-28 1999-10-15 胆汁酸取代的苯基链烯酰基胍、其制备方法、其作为药物或诊断剂的应用以及含有它们的药物

Country Status (22)

Country Link
US (1) US6166002A (enExample)
EP (1) EP1124841B1 (enExample)
JP (1) JP4616479B2 (enExample)
KR (1) KR20010085973A (enExample)
CN (1) CN1325403A (enExample)
AT (1) ATE236191T1 (enExample)
AU (1) AU757365B2 (enExample)
BR (1) BR9914929A (enExample)
CA (1) CA2349523A1 (enExample)
CZ (1) CZ20011429A3 (enExample)
DE (2) DE19849722A1 (enExample)
DK (1) DK1124841T3 (enExample)
ES (1) ES2191466T3 (enExample)
HK (1) HK1041271A1 (enExample)
HU (1) HUP0103751A3 (enExample)
ID (1) ID29025A (enExample)
PL (1) PL348108A1 (enExample)
PT (1) PT1124841E (enExample)
RU (1) RU2232769C2 (enExample)
TR (1) TR200101163T2 (enExample)
WO (1) WO2000024761A1 (enExample)
ZA (1) ZA200103106B (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19941764A1 (de) 1999-09-02 2001-03-15 Aventis Pharma Gmbh Substituierte Acylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikamente oder Diagnostika sowie sie enthaltende Medikamente
EP1646371A4 (en) 2003-06-26 2010-09-22 Biotron Ltd ANTIVIRAL COMPOSITIONS AND METHODS
DE10338554A1 (de) * 2003-08-22 2005-03-31 Aventis Pharma Deutschland Gmbh Pentafluorosulfanylphenyl-substituierte Benzoylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
US7390837B2 (en) 2004-01-30 2008-06-24 Ethicon, Inc. Germicidal compositions containing phenylmalonaldehyde-type compounds, or mixtures of phenylmalonaldehyde-type compounds and phthalaldehydes, and methods of using such compositions for disinfection or sterilization
US6891069B1 (en) 2004-01-30 2005-05-10 Ethicon, Inc. Synthesis of 4-substituted phthalaldehyde
US20050171215A1 (en) * 2004-01-30 2005-08-04 Ethicon, Inc. Germicidal compositions containing halogenated phthalaldehyes, and methods of using such compositions for disinfection or sterilization
US7476767B2 (en) 2004-01-30 2009-01-13 Ethicon, Inc. Alpha-hydroxy sulfonate aldehydes, germicidal compositions containing the alpha-hydroxy sulfonate aldehydes, or mixtures of alpha-hydroxy sulfonate aldehydes and phthalaldehydes, and methods of using the compounds or compositions for disinfection or sterilization
US7291649B2 (en) 2005-06-29 2007-11-06 Ethicon, Inc. Forming germicidal aromatic dialdehydes with acetals
CZ301037B6 (cs) * 2007-09-06 2009-10-21 Vysoká škola chemicko-technologická v Praze Amidové konjugáty steroidních a žlucových kyselin s D-glukosaminem a zpusob jejich prípravy
EP3351248B1 (en) 2008-12-31 2021-06-09 Ardelyx, Inc. Compounds and methods for inhibiting nhe-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
WO2018129556A1 (en) 2017-01-09 2018-07-12 Ardelyx, Inc. Compounds and methods for inhibiting nhe-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
KR102287207B1 (ko) 2013-04-12 2021-08-09 알데릭스, 인코포레이티드 Nhe3-결합 화합물 및 포스페이트 수송을 저해하는 방법
JP2020505333A (ja) 2017-01-09 2020-02-20 アルデリックス， インコーポレイテッド Ｎｈｅ媒介性アンチポートの阻害薬
CN110267944B (zh) 2017-01-09 2024-03-08 阿德利克斯股份有限公司 可用于治疗胃肠道病症的化合物
WO2020041673A1 (en) 2018-08-23 2020-02-27 President And Fellows Of Harvard College Compositions and methods related to cholic acid-7-sulfate as a treatment for diabetes
US12419897B2 (en) 2018-12-04 2025-09-23 President And Fellows Of Harvard College Synthetic derivatives of cholic acid 7-sulfate and uses thereof
EP3972599B1 (en) 2019-05-21 2025-10-22 Ardelyx, Inc. Combination for lowering serum phosphate in a patient

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW289021B (enExample) * 1993-05-08 1996-10-21 Hoechst Ag
US5792635A (en) * 1995-06-07 1998-08-11 Magainin Pharmaceuticals, Inc. Method of inhibiting the sodium/proton exchanger NHE3 and method of inhibiting growth by administering squalamine
JPH0959162A (ja) * 1995-08-28 1997-03-04 Makoto Takahashi 胆石溶解剤
DE19633966A1 (de) * 1996-08-22 1998-02-26 Hoechst Ag Phenylsubstituierte Alkenylcarbonsäure-guanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament

Also Published As

Publication number Publication date
DE59904875D1 (de) 2003-05-08
ATE236191T1 (de) 2003-04-15
WO2000024761A1 (de) 2000-05-04
AU6203299A (en) 2000-05-15
US6166002A (en) 2000-12-26
ZA200103106B (en) 2002-08-28
HUP0103751A3 (en) 2002-12-28
DK1124841T3 (da) 2003-07-28
EP1124841B1 (de) 2003-04-02
RU2232769C2 (ru) 2004-07-20
BR9914929A (pt) 2001-07-10
JP2002528460A (ja) 2002-09-03
AU757365B2 (en) 2003-02-20
HUP0103751A2 (hu) 2002-04-29
HK1041271A1 (zh) 2002-07-05
TR200101163T2 (tr) 2001-08-21
ES2191466T3 (es) 2003-09-01
KR20010085973A (ko) 2001-09-07
PL348108A1 (en) 2002-05-06
CZ20011429A3 (cs) 2001-08-15
JP4616479B2 (ja) 2011-01-19
DE19849722A1 (de) 2000-05-04
CA2349523A1 (en) 2000-05-04
EP1124841A1 (de) 2001-08-22
PT1124841E (pt) 2003-08-29
ID29025A (id) 2001-07-26

Similar Documents

Publication Publication Date Title
CN1325403A (zh) 胆汁酸取代的苯基链烯酰基胍、其制备方法、其作为药物或诊断剂的应用以及含有它们的药物
EP0873309B1 (fr) Derives 3-spiro-indolin-2-one comme ligands des recepteurs de la vasopressine et/ou de l'ocytocine
IL100240A (en) Bile acid derivatives process for their preparation and use of these compounds as pharmaceuticals
NZ516131A (en) Indole derivatives and their use for the treatment of osteoporosis amongst other applications
JP4833471B2 (ja) 胆汁酸との４−ベンジルアミノキノリン抱合体およびそれらのヘテロ類似体、それらの製造法、それらの化合物を含有する薬剤ならびにそれらの使用
JPH07119230B2 (ja) 骨吸収阻害剤としてのビスホスホン酸類のアシルオキシメチルエステル
US6451781B1 (en) Substituted acylguanidines, process for their preparation, their use as medicaments or diagnostics, and medicaments comprising them
CN1131238C (zh) 3－取代－d－高－1,3,5(10)－雌三烯衍生物
CN103180288B (zh) 具有生物学特性的二萜类衍生物
CN1371387A (zh) 胆汁酸衍生物的制备方法
MXPA01004147A (en) Bile-acid substituted phenyl alkenoyl guanidines, method for the production thereof, use thereof as medicaments or diagnostic agents and medicaments that contain them
EP0590489B1 (en) New cyclopentanperhydrophenanthren-17beta-(hydroxy or alkoxy)-17alpha-(aryl or heterocyclyl)-3beta-derivatives active on the cardiovascular system, processes for their preparation and pharmaceutical compositions containing same
JP2001520235A (ja) エストラ−１，３，５（１０）−トリエン−７α−チオエーテル
CN117946199A (zh) 一种屈螺酮关键中间体的制备方法
JP2009501175A (ja) 化合物ａ−３４８４４１の改善された結晶形態
JPWO1998011124A1 (ja) ３−置換−ｄ−ホモ−１，３，５，（１０）−エストラトリエン誘導体

Legal Events

Date Code Title Description
C06 Publication
C10 Entry into substantive examination
PB01 Publication
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1041271

Country of ref document: HK

AD01 Patent right deemed abandoned
C20 Patent right or utility model deemed to be abandoned or is abandoned